References
Weart CW, Leider H. Opportunities for pharmacists to aid in the management of acid-peptic disorders. Dis Manage Health Outcomes 2004; 12(4): 239–47
Pinson JB, Weart CW. Acid-peptic products. In: Covington TR, Berardi RR, Young LL, et al., editors. Handbook of nonprescription drugs. Washington, DC: American Pharmaceutical Association, 2002: 193–224
ASHP Commission on Therapeutics. ASHP therapeutic position statement on the identification and treatment of Helicobacter-associated peptic ulcer disease in adults. Am J Health Syst Pharm 2001; 58(4): 331–7
Howden CW, Hunt RW. Guidelines for the management of Helicobacter pylori infection. Am J Gastroenterol 1998; 93: 2330–8
Kahrilas PJ. Gastroesophageal reflux disease and its complications. In: Feldman M, Scharschmidt BF, Sleisenger MH, editors. Sleisenger & Fordtran’s gastrointestinal and liver disease. Philadelphia (PA): WB Saunders Company, 1998: 498–507
Soll AH, for the Practice Parameters Committee of the American College of Gastroenterology. Consensus statement: medical treatment of peptic ulcer disease: practice guidelines. JAMA 1996; 275: 622–9
Lanza FL. A guideline for the treatment and prevention of NSAID-induced ulcers. Members of the Ad Hoc Committee on Practice Parameters of the American College of Gastroenterology. Am J Gastroenterol 1998; 93: 2037–46
DeVault KR, Castell DO. Updated guidelines for the diagnosis and treatment of gastroesophageal reflux disease. Am J Gastroenterol 2005 Jan; 100(1): 190–200
Berardi RR. A critical evaluation of proton pump inhibitors in the treatment of gastroesophageal reflux disease. Am J Manag Care 2000; 6(9 Suppl.): S491–505
Williams DB. Gastroesophageal reflux disease. In: DiPiro JT, Talbert RL, Yee GC, et al., editors. Pharmacotherapy: a pathophysiologic approach. Stamford (CT): Appleton & Lange, 1999: 532–47
Kahrilas PJ. Gastroesophageal reflux disease and its complications. In: Feldman M, Scharschmidt BF, Sleisenger MH, editors. Sleisenger & Fordtran’s gastrointestinal and liver disease. Philadelphia (PA): WB Saunders Company, 1998: 498–507
Kahrilas PJ. Gastroesophageal reflux disease. JAMA 1996; 276: 983–8
Berardi RR. Peptic ulcer disease. In: DiPiro JT, Talbert RL, Yee GC, et al., editors. Pharmacotherapy: a pathophysiologic approach. Stamford (CT): Appleton & Lange, 1999: 548–70
Levin TR, Schmittdiel JA, Henning JM, et al. A cost analysis of a Helicobacter pylori eradication strategy in a large health maintenance organization. Am J Gastroenterol 1998; 93: 743–7
Jones GT, Morreale AP. Cost-benefit computer modeling of Helicobacter pylori testing and treatment in patients on long-term H2-blocker prophylaxis. J Manag Care Pharm 2000; 6: 383–9
Rights and permissions
About this article
Cite this article
Pharmacists have many opportunities to aid in the management of acid-peptic disorders. Drugs Ther. Perspect 21, 23–26 (2005). https://doi.org/10.2165/00042310-200521050-00008
Published:
Issue Date:
DOI: https://doi.org/10.2165/00042310-200521050-00008